



Attorney Docket No. 314572-105

Gp/1614

JUN 06 2002

TECH CENTER 1600/2900


RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Franklin, et al. : Group Art Unit No.: 1614  
Serial No.: 09/938,269 : Examiner: Unknown  
Filed: August 23, 2001  
For: Treatment of Trauma

U.S. Patent and Trademark Office  
Box Sequence, P.O. Box 2327  
Arlington, VA 22202

I hereby certify that this correspondence is being deposited with sufficient postage with the United States Postal Service as first-class mail in an envelope addressed to: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202 on May 29, 2002.

By:   
Sally B. Hansen


TRANSMITTAL LETTER

Transmitted herewith are the following documents in the above-identified application:


- Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures and copy of Notice;
- CRF diskette and paper copy.
- Acknowledgment postcard.

Applicants request that any additional fees required by these papers be charged, or any overpayment be credited, to Deposit Account No. 04-0480.

Respectfully submitted,

  
Arthur E. Jackson  
Registration No. 34,354  
Attorney for Applicant

DECHERT  
P. O. Box 5218  
Princeton, NJ 08543  
Attn: Arthur E. Jackson, Esq.  
(609) 620-3254  
Fax: (609) 620-3259



Docket No. 314572-105

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Franklin, et. al.  
Serial No.: 09/938,269  
Filed: August 23, 2001  
For: Treatment of Trauma

Commissioner for Patents  
Washington, DC 20231

RECEIVED  
JUN 06 2002  
TECH CENTER 1600/2900

**RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE  
AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Sir:

This is in reply to the communication mailed April 3, 2002 from the Patent Office, entitled "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures." A copy of the Notice is enclosed.

Submitted herewith is the "Sequence Listing" in computer readable form in accordance with the requirements of 37 CFR §§ 1.821-1.825. Please replace the Sequence Listing with the enclosed substituted Sequence Listing.

**STATEMENT**


Applicant hereby states that the enclosed CRF diskette and the paper copy submitted herewith are the same and contains no new matter.

Respectfully submitted,

Arthur E. Jackson  
Registration No. 34,354  
Attorney for Applicants

Date: May 29, 2002

DECHERT  
Princeton Pike Corporate Center  
PO Box 5218  
Princeton, NJ 08543-5218  
Fax: 609.620.3259



UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
Page 1 of 2

JUN 06 2002

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

| APPLICATION NUMBER | FILING/RECEIPT DATE | FIRST NAMED APPLICANT | ATTORNEY DOCKET NUMBER |
|--------------------|---------------------|-----------------------|------------------------|
| 09/938,269         | 08/23/2001          | Richard Franklin      | 314572-105             |

25561  
ALLEN BLOOM  
C/O DECHERT  
PRINCETON PIKE CORPORATION CENTER  
P.O. BOX 5218  
PRINCETON, NJ 08543-5218

CONFIRMATION NO. 1197  
FORMALITIES LETTER



\*OC000000007776446\*

Date Mailed: 04/03/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

**For questions regarding compliance to these requirements, please contact:**

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

*James*  
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE